Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET ® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown ...

The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of ...

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

Vanderbilt University Medical Center is launching Masimo Radius VSM™ advanced wireless patient-worn vital signs monitoring ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

4 analysts have expressed a variety of opinions on Masimo MASI over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of their ...

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement. Analysts estimate that Masimo will ...

Apple won the case, though was only awarded a nominal $250, which is the smallest amount it was possible for the court to order. In other words, yes Masimo did in infringe Apple’s patents, but there ...

Masimo executives are back calling their consumer audio business Sound United, with a senior executive on a conference call ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.